AxoGen, Inc. (AXGN)

6,51 -0,43 (-6,27 %) À partir de 02:33PM EDT. Marché ouvert.

AxoGen, Inc.

13631 Progress Boulevard
Suite 400
Alachua, FL 32615
United States
386 462 6800
https://www.axogeninc.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 426

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Ms. Karen Zaderej	Chairman, President & CEO	852,18k	150,31k	1962
Mr. Michael Donovan	Vice President of Operations	406,02k	30,75k	1965
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.	Chief Financial Officer	S.O.	S.O.	1975
Mr. Harold D. Tamayo	Vice President of Finance & Investor Relations	S.O.	S.O.	S.O.
Mr. Marc A. Began	Executive VP, General Counsel & Chief Compliance Officer	S.O.	S.O.	1968
Ms. Doris Quackenbush	Vice President of Sales	S.O.	S.O.	S.O.
Mr. Jens Schroeder Kemp	Chief Marketing Officer	S.O.	S.O.	S.O.
Mr. Erick DeVinney	Chief Innovation Officer	S.O.	S.O.	1976
Dr. Ivica Ducic M.D., Ph.D.	Chief Medical Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Gouvernance d’entreprise

L’ISS Governance QualityScore de AxoGen, Inc. en date du 1 avril 2024 est 2. Les scores principaux sont Audit : 1; Société : 4; Droits des actionnaires : 1; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.